China Economic Net Beijing, January 14th, by Sunnyou Medical: Last night, Sunnyou Medical disclosed an announcement regarding the share reduction plan of its shareholders.
The company's shareholder, Anyang Qixu Trade Consulting Service Center (Limited Partnership) ("Anyang Qixu" for short), holds 8,602,320 shares of the company, accounting for 5.38% of the company’s total share capital. These shares were obtained prior to the company’s initial public offering and were released from lock-up and became tradable on March 31, 2024.
Due to its own capital needs, Anyang Qixu plans to reduce its holdings in the company by no more than 4,800,000 shares through centralized bidding and block trading. The total reduction ratio will not exceed 3% of the company's total share capital and will be implemented within 3 months after 15 trading days from the date of the announcement of the reduction plan. Among this, the reduction through centralized bidding will not exceed 1,600,000 shares, accounting for no more than 1% of the company's total share capital; the reduction through block trading will not exceed 3,200,000 shares, accounting for no more than 2% of the company's total share capital.
Based on the closing price of Sunnyou Medical (Xiangyu Medical Co., Ltd.) on January 13 at 86.74 yuan, the cash-out amount of Anyang Qixu is approximately 416 million yuan.
The announcement shows that Anyang Qixu and Henan Xiangyu Health Industry Management Co., Ltd. are both controlled by the company's actual controller, He Yongzheng and Guo Junling.
Sunnyou Medical was listed on the STAR Market of the Shanghai Stock Exchange on March 31, 2021, with an issuance of 40,000,000 shares (all new shares, no old shares were transferred). The issue price was 28.82 yuan per share. The sponsor institution was Haitong Securities Co., Ltd. (now renamed Guotai Haitong Securities Co., Ltd.), and the sponsor representatives were Liu Jun and Cen Pingyi.
Sunnyou Medical's initial public offering raised a total of 1.1528 billion yuan; after deducting issuance expenses, the net proceeds amounted to 1.0496566 billion yuan. Sunnyou Medical’s final net proceeds exceeded the original plan by 341.6566 million yuan. According to the prospectus released by Sunnyou Medical on March 25, 2021, the company planned to raise 708 million yuan for projects including the production technology renovation of intelligent rehabilitation medical devices, the production and construction project of elderly care and postpartum rehabilitation medical equipment, the R&D and exhibition center construction project for rehabilitation equipment, the (Southwest) R&D and sales center project for intelligent rehabilitation equipment, and operational reserve funds.
Sunnyou's total issuance expenses amounted to 103.1434 million yuan, including 79.3904 million yuan for sponsorship and underwriting fees.